Prognostic significance of BRAF mutation alone and in combination with microsatellite instability in stage III colon cancer.

BRAF-mutated cancers demonstrated a trend toward poorer outcomes, however, when adjusted for clinicopathological factors and chemotherapy, BRAF mutation was not found to be an independent prognostic biomarker in stage III colon cancer, even when combined with MSI.